@Lybsoo Innate Pharma Congress Immunology ... that one could be about the SCCHN combo trial cetuximab + monalizumab which did aleady pass phase 2 target of 25% ORR (refer to last #AACR18 poster #CT158 in April: 8 partial responses out of 26 patients in a set of preliminary data); next step would be a registrational study

#NuTone #CT158 #Turn & #Twist #Floor #Brush: Price: What started with the world’s first door chime eight decades… goo.gl/U4b7iJ